Fluorescent Silicon-Based Nanocarriers for Drug Delivery in Acute Myocardial Infarction

Acute myocardial infarction (AMI) results from acute coronary artery occlusion, leading to myocardial ischemia and necrosis. Ciprofol, an intravenous anesthetic, has antioxidant, anti-lipid peroxidation, anti-calcium overload, and anti-inflammatory properties. Effective drug delivery systems are crucial for addressing myocardial ischemia–reperfusion injury (MIRI). In this study, we developed an efficient composite drug delivery system by combining the high surface area of metal–organic frameworks (MOFs) with the biocompatibility and fluorescence properties of silica-based materials. We modified (3-aminopropyl)trimethoxysilane (APTMS) with compound 1 to create the APTMS-1@CP1 composite, which effectively encapsulates and transports Ciprofol. The composite exhibited strong fluorescence with peaks at 326 nm and 450 nm, a BET surface area of 689.7 m²/g, and a pore size of 5.1 nm, confirming its suitability for drug delivery. The drug loading capacity and controlled release properties were excellent, and fluorescence cycling tests showed no significant intensity decrease after five cycles, ensuring stability. The nitrogen adsorption/desorption isotherms indicated mesoporous material behavior, facilitating efficient encapsulation. In a H9c2 cell model of MIRI, pretreatment with APTMS-1@CP1@Ciprofol significantly restored cell viability compared to the MIRI group. The composite also reduced malondialdehyde (MDA) levels and inflammatory markers (IL-6, TNF-α), demonstrating its potential in alleviating oxidative stress and inflammation. These findings underscore the composite’s potential for treating cardiovascular diseases, especially myocardial ischemia–reperfusion injury, due to its high drug loading, controlled release, and therapeutic efficacy.